News

Triple Therapy Boosts HCV Response After Transplant

Publish date: November 20, 2012

 

AT THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

Dr. Burton disclosed that he is an investigator in a clinical trial sponsored by Vertex Pharmaceuticals, which makes telaprevir.☐

Pages

Recommended Reading

Drug-Drug Interactions Added to Hepatitis C Drug Label
MDedge Family Medicine
CDC Urges Hep C Test for Baby Boomers
MDedge Family Medicine
Pretreatment Care Predicts HCV Outcomes
MDedge Family Medicine
Analysis Details the GI Disease Burden in U.S.
MDedge Family Medicine
Fatty Liver Disease Cited for Rise in Hepatocellular Carcinoma
MDedge Family Medicine
Acetaminophen Liver Failure Least Likely to Get Transplant
MDedge Family Medicine
Benefit of Young Liver Donors Scrutinized in Study
MDedge Family Medicine
Excessive Acetaminophen Dosing Seen Among Inpatients
MDedge Family Medicine
Panel Calls for More Safety Data for Hepatitis B Vaccine
MDedge Family Medicine
Investigational HCV Regimens Ditch the Interferon
MDedge Family Medicine